Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Poly-N-acetylglucosamine (p-GlcNAc) is a naturally derived polysaccharide-based hemostatic agent produced in a nanofiber format, typically isolated from marine microalgae. Developed primarily by Marine Polymer Technologies, it is used to achieve rapid surface hemostasis and treat various types of wounds, including surgical sites, trauma, and chronic ulcers. The material functions by activating platelets and providing a catalytic surface that accelerates the intrinsic coagulation cascade, specifically through the activation of Factor XII (Hageman factor), which leads to increased thrombin generation and fibrin polymerization. Notably, its efficacy is maintained in patients receiving antiplatelet therapy (e.g., aspirin or clopidogrel) and those with coagulopathies. It is available in various formulations such as patches (Syvek) for vascular access site closure and topical membranes (Talymed) for wound care.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on poly-N-acetylglucosamine.